Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

Nature Medicine

Volumn 2, Issue 10, 1996, Pages 1096-1103

  Gabrilovich, Dmitry I ^a,b   Chen, Hailei L ^a   Girgis, Khaled R ^a   Cunningham, H Thomas ^a   Meny, Geralyn M ^a   Nadaf, Sorena ^a,b   Kavanaugh, Denise ^a   Carbone, David P ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN; VASCULOTROPIN;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL MATURATION; DENDRITIC CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANTIGEN PRESENTATION; BASE SEQUENCE; CELL DIFFERENTIATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DENDRITIC CELLS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; HEMATOPOIETIC CELL GROWTH FACTORS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNE TOLERANCE; LYMPHOKINES; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT PROTEINS; T-LYMPHOCYTE SUBSETS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0029842830     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1096-1096     Document Type: Article

References (45)

1. Ioannides, C. & Whiteside, T. T cell recognition of human tumors: Implication for molecular immunotherapy of cancer. Clin. Immunol. Immunopathol. 66, 91-106 (1993).
2. Cozzolino, F. et al. Characterization of cells from invaded nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response. J. Exp. Med. 166, 303-318 (1987).
3. Belldegrun, A., Kasid, A., Uppenkamp, M., Topalian, S.L. & Rosenberg, S.A. Human tumor infiltrating lymphocytes: Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J. Immunol. 42, 4520-4526 (1989).
4. Gabrilovich, D., Ciernik, F. & Carbone, D.P. Dendritic cells in anti-tumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell. Immunol. 170, 101-110 (1996).
5. Huang, A.Y.C. et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965 (1994).
6. Rock, K.L., Rothstein, L., Gamble, S. & Fleishacker, C. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J. Immunol. 150, 438-446 (1993).
7. Tan, K.C., Hosoi, J., Grabbe, S., Asahina, A. & Granstein, R.D. Epidermal cell presentation of tumor-associated antigens for induction of tolerance. J. Immunol. 153, 760-767 (1994).
8. Watson, G. & Lopez, D.M. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses. J. Immunol. 155, 3124-3134 (1995).
9. Alcalay, J. & Kripke, M.L. Antigen-presenting activity of draining lymph node cells from mice painted with a contact allergen during ultraviolet carcinogenesis. J. Immunol. 146, 1717-1721 (1991).
10. Erroi, A. et al. IL1 and IL6 released by tumor-associated macrophages from human ovarian carcinoma. Int. J. Cancer 41, 65-68 (1989).
11. Steinman, R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271-296 (1991).
12. Knight, S.C. & Stagg, A.J. Antigen-presenting cell types. Curr. Opin. Immunol. 5, 374-382 (1993).
13. Austin, J.M. The dendritic cell system and anti-tumor immunity. In Vivo 7, 193-202 (1993).
14. Zitvogel, L. et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183, 87-97 (1996).
15. Mayordomo, J.I. et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1, 1297-1302 (1995).
16. Hsu, F.J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52-58 (1996).
17. Tas, M., Simons, P., Balm, F. & Drexhage, H. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: In vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol. Immunother. 36, 108-114 (1993).
18. Reynolds, N.J. et al. Down-regulation of Langerhans cell protein kinase C-beta isoenzyme expression in inflammatory and hyperplastic dermatoses. Br. J. Dermatol. 133, 157-167 (1995).
19. Bergfelt, L., Emilson, A., Lindberg, M. & Scheynius, A. Quantitative and three-dimensional analysis of Langerhans cells in basal cell carcinoma: A comparative study using light microscopy and confocal laser scanning microscopy. Br. J. Dermatol. 130, 273-280 (1994).
20. Toriyama, K., Wen, D.R., Paul, E. & Cochra, A.J. Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin. J. Invest. Dermat. 100, 269S-273S (1993).
21. Gabrilovich, D.I., Nadaf, S., Corak, J. Berzofsky, J.A. & Carbone, D.P. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell. Immunol. 170, 111-120 (1996).
22. Caux, C., Dezutter-Dambuyant, C., Schmitt, D. & Banchereau, J. GM-CSF and TNF-α cooperate in the generation of dendritic cells. Nature 360, 258-261 (1992).
23. + progenitors in human bone marrow. J. Immunol. 149, 2681-2688 (1992).
24. Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179, 1109-1118 (1994).
25. Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M. & Heldin, C.-H. Different signal transduction properties of KDR and FLT1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269, 26988-26995 (1994).
26. Szabolcs, P. et al. Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate. Blood 87, 4520-4530 (1996).
27. Reid, C.D.L. et al. Identification of hematopoietic progenitors of macrophages and dendritic Langerhans cells (DL-CFU) in human bone marrow and peripheral blood. Blood 76, 1139-1149 (1990).
28. Roth, P. & Stanley, E.R. The biology of CSF-1 and its receptor. Curr. Topics Microb. Immunol. 181, 141-155 (1992).
29. Rozenzwajg, M., Canque, B. & Gluckman, J.C. Human dendritic cells differentiation pathway from CD34+ hematopoietic precursor cells. Blood 87, 535-544 (1996).
30. Leung, D.W., Cachianes, G., Kuang, W.-J., Goeddel, D.V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309 (1989).
31. Connolly, D.T. et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84, 1470-1478 (1989).
32. Takeshita, S. et al. Therapeutic angiogenesis: A single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 93, 662-670 (1994).
33. Ferrara, N., Houck, K., Jakeman, J. & Leung, D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrine Rev. 13, 18-32 (1992).
34. Kondo, S., Asano, M., Matsuo, K., Ohmori, I. & Suzuki, H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochem. Biophys. Acta 1221, 211-214 (1994).
35. Takano, S. et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 56, 2185-2190 (1996).
36. Shen, H. et al. Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood 81, 2767-2773 (1993).
37. - stem/progenitor cells. Oncogene 12, 903-913 (1996).
38. Katoh, O., Tauchi, H., Kawaishi, K., Kimura, A. & Satow, Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 55, 5687-5692 (1995).
39. Broxmeyer, H.E. et al. Myeloid progenitor cells regulatory effects of vascular endothelial cell growth factor. Inter. J. Hematol. 62, 203-215 (1995).
40. Axelsson, K. et al. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J. Natl. Cancer Inst. 87, 997-1008 (1995).
41. Bossi, P. et al. Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res. 55, 5049-5053 (1995).
42. Bochner, B.H. et al. Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J. Natl. Cancer Inst. 87, 1603-1612 (1995).
43. Gazdar, A.F. & Oie, H.K. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 46, 6011-6012 (1986).
44. + T cells. J. Clin. Invest. 94, 797-807 (1994).
45. Hayhoe, F.G.J. & Quaglino, D. Haematological Cytochemistry. (Churchill Livingston, London, 1988).